STOCK TITAN

Bio-Techne (TECH) executive nets shares from 794 RSU exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bio-Techne Corp executive Steven C. Crouse reported routine equity compensation activity involving company stock. On May 1, 2026, he exercised 794 Restricted Stock Units, which converted into an equal number of Bio-Techne common shares.

To cover tax obligations, 311 common shares were disposed of through a tax-withholding transaction, a non-market event that does not represent an open-market sale. Following these transactions, Crouse directly holds 6,688 shares of common stock, alongside multiple option and restricted stock unit awards that vest over several future dates.

Positive

  • None.

Negative

  • None.
Insider Crouse Steven C.
Role President - Diag & Spatial Bi
Type Security Shares Price Value
Exercise Restricted Stock Units 794 $0.00 --
Exercise Common Stock 794 $0.00 --
Tax Withholding Common Stock 311 $55.02 $17K
holding Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Option (right to buy) -- -- --
Holdings After Transaction: Restricted Stock Units — 794 shares (Direct, null); Common Stock — 6,688 shares (Direct, null); Stock Option (right to buy) — 3,856 shares (Direct, null); Performance Restricted Stock Units — 2,387 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 794 restricted stock units vest on 5/1/2026 and 5/1/2027. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028. 1,379 restricted stock units vest on 8/15/2026. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027. 100% vested. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029. Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
RSUs exercised 794 shares Restricted Stock Units converted to common stock on May 1, 2026
Shares withheld for taxes 311 shares Tax-withholding disposition (code F) on May 1, 2026
Common shares held after 6,688 shares Direct ownership following reported transactions
Option strike price $57.82/share Stock option on Common Stock expiring March 2, 2036
Option strike price $53.60/share Stock option on Common Stock expiring August 15, 2035
Largest option block 24,560 underlying shares Stock option at $94.52/share expiring August 15, 2029
RSU block 6,529 underlying shares Restricted Stock Units with exercise price $0.00
Performance RSUs 2,387 underlying shares Performance Restricted Stock Units on Common Stock
Restricted Stock Units financial
"794 restricted stock units vest on 5/1/2026 and 5/1/2027."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Performance Restricted Stock Units, underlying security title Common Stock"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Option (right to buy) financial
"Stock Option (right to buy), underlying security title Common Stock"
tax-withholding disposition financial
"transaction_action: tax-withholding disposition, code F"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion, code M"
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Crouse Steven C.

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President - Diag & Spatial Bi
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026M794A(1)6,688D
Common Stock05/01/2026F311D$55.026,337D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/01/2026M794 (2) (2)Common Stock794$0794D
Restricted Stock Units(1) (3) (3)Common Stock1,8001,800D
Restricted Stock Units(1) (4) (4)Common Stock1,3791,379D
Restricted Stock Units(1) (5) (5)Common Stock3,7373,737D
Restricted Stock Units(1) (6) (6)Common Stock6,5296,529D
Stock Option (right to buy)$97.13 (7)04/01/2028Common Stock3,8563,856D
Stock Option (right to buy)$120.46 (7)08/06/2028Common Stock19,03219,032D
Stock Option (right to buy)$94.52 (8)08/15/2029Common Stock24,56024,560D
Stock Option (right to buy)$84.61 (9)08/15/2030Common Stock12,64912,649D
Stock Option (right to buy)$73.46 (10)05/01/2031Common Stock7,3277,327D
Stock Option (right to buy)$74.91 (11)08/15/2034Common Stock17,13317,133D
Stock Option (right to buy)$48.61 (12)06/02/2035Common Stock5,4345,434D
Stock Option (right to buy)$53.6 (13)08/15/2035Common Stock19,15119,151D
Performance Restricted Stock Units(1) (14) (14)Common Stock2,3872,387D
Restricted Stock Units(1) (15) (15)Common Stock735735D
Stock Option (right to buy)$57.82 (16)03/02/2036Common Stock1,9111,911D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
2. 794 restricted stock units vest on 5/1/2026 and 5/1/2027.
3. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.
4. 1,379 restricted stock units vest on 8/15/2026.
5. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
6. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
7. 100% vested.
8. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
9. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
10. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
11. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
12. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
13. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
14. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
15. 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.
16. Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
/s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney previously filed.05/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bio-Techne (TECH) executive Steven C. Crouse report in this Form 4?

Steven C. Crouse reported equity compensation activity, including the exercise of 794 Restricted Stock Units into Bio-Techne common shares and related tax-withholding. These updates show changes in his holdings, not an open-market stock trade or new cash investment decision.

How many Bio-Techne shares did Steven C. Crouse acquire and dispose of?

He acquired 794 shares of Bio-Techne common stock through the exercise of Restricted Stock Units and had 311 shares withheld to satisfy tax obligations. The tax withholding is a non-market disposition tied to compensation, not a discretionary stock sale.

How many Bio-Techne common shares does Steven C. Crouse hold after these transactions?

After the reported activity, Steven C. Crouse directly holds 6,688 shares of Bio-Techne common stock. This figure reflects the net result after exercising 794 Restricted Stock Units and the withholding of 311 shares for taxes on May 1, 2026.

What does the tax-withholding transaction mean in Steven C. Crouse’s Bio-Techne filing?

The Form 4 shows a code F transaction where 311 shares of Bio-Techne common stock were used to pay tax obligations. This tax-withholding disposition is part of equity compensation processing and does not represent an open-market sale or trading decision.

What derivative or equity awards does Steven C. Crouse retain at Bio-Techne?

The filing lists multiple stock options, Restricted Stock Units, and Performance Restricted Stock Units tied to Bio-Techne common stock, with exercise prices such as $57.82 and $53.60 and various vesting schedules extending to dates like 2036-03-02.

Are the transactions in this Bio-Techne Form 4 open-market buys or sells?

No open-market trades are shown. The key events are a derivative exercise of 794 Restricted Stock Units (code M) and a tax-withholding disposition of 311 shares (code F), both standard mechanisms in equity compensation rather than discretionary market purchases or sales.